The Rothenberg CURED Research Laboratory has several broad research areas and objectives, including:

Epigenetic Basis of Allergic Disease and Responses

  • Identifying epigenetic mechanisms of allergic responses

Genetic Basis of Allergic Disease

  • Identifying genes and key check points that predispose to eosinophilic and other allergic disorders
  • Elucidating gene-environment interactions

Immunopathogenesis of Allergic Inflammation

  • Elucidating the cellular and molecular processes involved in allergic responses in the gastrointestinal tract and lung
  • Developing novel models of allergic responses in vivo and in vitro
  • Testing the importance of key molecules including chemokines, cytokines and adhesion molecules in immunity

Impaired Barrier Function

  • Elucidating the role of impaired barrier function in allergic inflammation, with focus on proteases and anti-proteases

Pathogenesis of Eosinophilic Gastrointestinal Disorders

  • Biochemically characterizing the transcriptional programs, regulating molecules and signal transduction mechanisms responsible for eosinophil development and activation
  • Translating bench discoveries into novel therapeutics that treat inflammatory diseases such as eosinophilic esophagitis (EoE) and hypereosinophilic syndromes (HES).

Precision and Predictive Medicine

  • Conducting big data (genomics, proteonomics) analyses of allergic disease with a focus on eosinophilic esophagitis (EoE)
  • Translating research findings into improved diagnostics (Learn more)

Proteases and Protease Inhibitors in Inflammation

  • Investigating the role of proteases and protease inhibitors in immunity

Identifying Environmental Factors Involved in Allergic Diseases

Characterizing Microbiome Identity and Function in Esophagus and Allergic Immunity

 

Rothenberg CURED Research Laboratory

The mission of the laboratory, supported by the Campaign Urging Research for Eosinophilic Diseases (CURED), is to control the activity of dysregulated proteases in the esophagus as a target therapy for eosinophilic esophagitis (EoE). The laboratory comprises researchers from diverse disciplines who work together synergistically and collaborate with outside partners, including pharmaceutical companies and other academic institutions.

  • Produce recombinant proteins and small molecules in amounts sufficient for preclinical usage
  • Test the activity of candidate proteins and other chemical entities in cellular systems in vitro, as well as translational ex vivo and in vivo disease models
  • Develop novel approaches for esophageal specific delivery of drugs
  • Clinical studies
  • Proof-of-concept studies designed to test hypotheses developed in the laboratory
  • Examine the impact and consequences of eosinophil-ablative therapy in humans
  • Design novel therapeutic interventions
  • Apply precision therapy to allergic disease
  • Use molecular diagnostics, genomics and transcriptomics to endotype and predict prognosis and therapeutic responses
  • Bring molecular medicine, as done in cancer field, to the forefront of allergic diseases